The participations - sustainable

Company Cell Therapy focuses on the development and commercialization of bone marrow transplant (BMT) therapies and other adaptive cell therapies. Its lead candidate product is in a pivotal Phase III clinical trial for elderly people with relapsed or refractory acute myeloid leukemia for BMT conditioning.

The Company Cell Therapy develops focused radiation therapies based on its own technology platform. The company is currently researching a clinical-stage, multi-disease, multi-target pipeline of antibody-radiation conjugates that can be used for targeted conditioning and as therapeutic agents. The conjugates can potentially be used either in combination with other therapeutic modalities (in collaboration with other companies) or as a single agent for patients with hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. The conjugates offer highly effective and selective forms of radiation therapy that enable precise targeting of their proven therapeutic power to tumors and synergistic potential with other therapeutic modalities that cannot be achieved with conventional external beam radiation, cytotoxic chemotherapy or biological therapies. Through its technology platform, the company aims to use multiple radioisotopes to meet the specific requirements of the desired indication.

The company is a leader in using a potent alpha-emitting radioisotope and has demonstrated the ability to isotopically target both hematologic and solid tumors.

The company’s lead product candidate is in Phase 3 clinical trials for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy.

This company’s new drug development approach is based on the use of a proprietary controlled release technology that improves the way drugs are dosed and released.

The current drug is a once-per-night extended-release formulation. The once-per-night drug may be safer due to consequences associated with the dosing regimen of the previously approved twice-per-night product.

Company Fusion Protein Therapeutics focuses on the development and commercialization of targeted fusion protein therapeutics (TFPTs) for the treatment of cancer patients.

The company’s lead product candidates include a locally administered targeted fusion protein that is in Phase III clinical trials for the treatment of Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) and a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors.

While BCG is effective in many patients, challenges with tolerability have been observed and many patients experience disease recurrence. When BCG is not effective or a patient can no longer receive BCG, the recommended treatment option is radical cystectomy, the complete removal of the bladder.